| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/LEU.2012.372 |
| P698 | PubMed publication ID | 23334362 |
| P50 | author | Sandra Sofia Mimoso Pinhanços | Q85925179 |
| P2093 | author name string | P Schneider | |
| R Pieters | |||
| J A P Spijkers-Hagelstein | |||
| R W Stam | |||
| P2860 | cites work | Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11 | Q24647711 |
| Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia | Q28273146 | ||
| Annexin 2 has a dual role as regulator and effector of v-Src in cell transformation | Q28570986 | ||
| Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer | Q28740545 | ||
| GenePattern 2.0 | Q29614171 | ||
| Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation | Q29617586 | ||
| Dasatinib: an anti-tumour agent via Src inhibition | Q33393621 | ||
| Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells | Q33504768 | ||
| Novel dual Src/Abl inhibitors for hematologic and solid malignancies | Q34121339 | ||
| Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer | Q35569694 | ||
| Tyrosine kinase inhibitors: a new approach for asthma | Q35692069 | ||
| H3K79 methylation profiles define murine and human MLL-AF4 leukemias | Q36991857 | ||
| Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia | Q38324952 | ||
| Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma | Q39827635 | ||
| Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. | Q40182148 | ||
| Design, synthesis, and structure-activity relationship exploration of 1-substituted 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one analogues as inhibitors of the annexin A2-S100A10 protein interaction. | Q42032160 | ||
| Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay | Q42032841 | ||
| Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants | Q42643970 | ||
| Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia | Q43228851 | ||
| Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia | Q44567802 | ||
| In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype | Q44719683 | ||
| Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia | Q44851706 | ||
| Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth | Q47770884 | ||
| A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. | Q53232081 | ||
| Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. | Q54327060 | ||
| A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. | Q54604759 | ||
| A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer | Q61872222 | ||
| Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants | Q77299310 | ||
| Structural basis for selective inhibition of Src family kinases by PP1 | Q78192599 | ||
| P433 | issue | 5 | |
| P921 | main subject | leukemia | Q29496 |
| phosphorylation | Q242736 | ||
| glucocorticoid resistance | Q11798714 | ||
| P304 | page(s) | 1063-1071 | |
| P577 | publication date | 2012-12-28 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia | |
| P478 | volume | 27 |
| Q53627616 | A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target. |
| Q37586765 | Annexin A2: its molecular regulation and cellular expression in cancer development |
| Q52652985 | Calcium channel α2δ1 subunit as a novel biomarker for diagnosis of hepatocellular carcinoma. |
| Q39108160 | Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL. |
| Q39377574 | Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma |
| Q92463707 | Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism |
| Q92347954 | Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia |
| Q35805960 | Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy |
| Q41712023 | Extracellular vesicles released from cells exposed to reactive oxygen species increase annexin A2 expression and survival of target cells exposed to the same conditions |
| Q47152778 | Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. |
| Q38091585 | In focus: MLL-rearranged leukemia. |
| Q89873581 | Integrated bioinformatics analysis of the crucial candidate genes and pathways associated with glucocorticoid resistance in acute lymphoblastic leukemia |
| Q98947319 | Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia |
| Q35176372 | LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients |
| Q104104744 | Mesoglycan exerts its fibrinolytic effect through the activation of annexin A2 |
| Q53763092 | Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia. |
| Q37377476 | Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells |
| Q64275561 | Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells |
| Q41870703 | Reactive oxygen species exert opposite effects on Tyr23 phosphorylation of the nuclear and cortical pools of annexin A2 |
| Q60947864 | S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer |
| Q38217719 | Src family kinases and their role in hematological malignancies |
| Q35942561 | The NIH-Industry New Therapeutic Uses Pilot Program: Demonstrating the Power of Crowdsourcing |
| Q37730023 | The evolution of clinical trials for infant acute lymphoblastic leukemia. |
| Q38423064 | The inflammatory actions of coagulant and fibrinolytic proteases in disease |
Search more.